Prostate Cancer Discoveries Digest Welcome to your monthly summary of the notable research studies and developments that help provide greater insight into prostate cancer causes, treatments, outcomes, and survivorship. See all Newsletters Jump To Jump To Join the Email List Welcome to the August 2025 edition of ZERO's Prostate Cancer Discoveries Digest! We've gathered the latest headlines on prostate cancer treatment, diagnostics, side effects, and more—delivered straight to your inbox. Know someone who could benefit from these updates? Forward this newsletter and help spread the word. ZERO Prostate Cancer does not endorse any particular study or finding in this issue. Genetics & Biomarkers Precision and Combination Strategies for Immune Checkpoint Inhibitors in Prostate Cancer A new study shows patients with metastatic castration-resistant prostate cancer (mCRPC) who have certain genetic or tumor features may benefit from dual immune checkpoint inhibitors. These findings highlight the need for biomarker testing to ensure equitable access to life-extending therapies. » Full Article from ASCO Diagnostics & Treatment PSMA PET/CT and Salvage Radiotherapy in Recurrent Prostate Cancer A PSMA PET/CT scan before starting treatment may better identify which prostate cancer patients with a recurrence will benefit from radiation therapy after surgery, real-world study findings suggest. » Full Article from Urology Times Health Equity Rural and Urban Differences in Prostate Cancer Recurrence A study found that rural patients had significantly higher rates of prostate cancer recurrence compared with urban patients. These findings highlight a need for more research to evaluate why this is happening and possible interventions to combat this disparity. » Full Article from JAMA Network Survivorship Does Preexisting Depression Impact Prostate Cancer Survival? A study found that prostate cancer patients with preexisting depression had a higher risk of mortality than those without preexisting depression. This points to the need to address mental health as a critical factor in prostate cancer care and survivorship. » Full Article from ASCO Diagnostics FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer The FDA has accepted a new drug application for an updated formulation of the PSMA PET imaging agent piflufolastat F 18 (Pylarify) used to detect prostate cancer. The new version is expected to improve patient access by increasing the number of doses per batch. » Full Article from Cancer Network Outcomes FDA grants fast track designation to HLD-0915 in mCRPC The FDA has granted Fast Track designation to HLD-0915, an investigational oral therapy for mCRPC. Preclinical studies showed tumor shrinkage and PSA declines, including in drug-resistant models. The agent is now being tested in a phase 1/2 trial to evaluate safety and early efficacy. » Full Article from Urology Times Health Equity Cancer Care Without a Safety Net—How Oncology Practices Confront the Gap Food insecurity disproportionately affects vulnerable populations with cancer, including rural communities, racial and ethnic minorities, and low-income patients. These disparities may worsen cancer outcomes without stronger federal, state, and community food programs. » Full Article from JAMA Network ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to replace medical professionals' or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan. Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
Welcome to the August 2025 edition of ZERO's Prostate Cancer Discoveries Digest! We've gathered the latest headlines on prostate cancer treatment, diagnostics, side effects, and more—delivered straight to your inbox. Know someone who could benefit from these updates? Forward this newsletter and help spread the word. ZERO Prostate Cancer does not endorse any particular study or finding in this issue. Genetics & Biomarkers Precision and Combination Strategies for Immune Checkpoint Inhibitors in Prostate Cancer A new study shows patients with metastatic castration-resistant prostate cancer (mCRPC) who have certain genetic or tumor features may benefit from dual immune checkpoint inhibitors. These findings highlight the need for biomarker testing to ensure equitable access to life-extending therapies. » Full Article from ASCO Diagnostics & Treatment PSMA PET/CT and Salvage Radiotherapy in Recurrent Prostate Cancer A PSMA PET/CT scan before starting treatment may better identify which prostate cancer patients with a recurrence will benefit from radiation therapy after surgery, real-world study findings suggest. » Full Article from Urology Times Health Equity Rural and Urban Differences in Prostate Cancer Recurrence A study found that rural patients had significantly higher rates of prostate cancer recurrence compared with urban patients. These findings highlight a need for more research to evaluate why this is happening and possible interventions to combat this disparity. » Full Article from JAMA Network Survivorship Does Preexisting Depression Impact Prostate Cancer Survival? A study found that prostate cancer patients with preexisting depression had a higher risk of mortality than those without preexisting depression. This points to the need to address mental health as a critical factor in prostate cancer care and survivorship. » Full Article from ASCO Diagnostics FDA Accepts NDA for New Formulation of PSMA PET Injection in Prostate Cancer The FDA has accepted a new drug application for an updated formulation of the PSMA PET imaging agent piflufolastat F 18 (Pylarify) used to detect prostate cancer. The new version is expected to improve patient access by increasing the number of doses per batch. » Full Article from Cancer Network Outcomes FDA grants fast track designation to HLD-0915 in mCRPC The FDA has granted Fast Track designation to HLD-0915, an investigational oral therapy for mCRPC. Preclinical studies showed tumor shrinkage and PSA declines, including in drug-resistant models. The agent is now being tested in a phase 1/2 trial to evaluate safety and early efficacy. » Full Article from Urology Times Health Equity Cancer Care Without a Safety Net—How Oncology Practices Confront the Gap Food insecurity disproportionately affects vulnerable populations with cancer, including rural communities, racial and ethnic minorities, and low-income patients. These disparities may worsen cancer outcomes without stronger federal, state, and community food programs. » Full Article from JAMA Network ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to replace medical professionals' or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan.
Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
